ARGX Looks 29.0% Undervalued on GF Value™
UBS upgraded argenx SE (ARGX) to Buy with a $1,400 price target, citing positive trial results for Vyvgart. ARGX's stock is trading at $1,048.84, 29.0% below its GF Value™ of $1,478.00. The company has a GF Score™ of 78, strong financial health, and a growing pipeline. Institutional interest remains high, with 8 gurus holding shares.
How this was made
The 30-second read
Why it matters
The upgrade could trigger buying pressure, especially from value‑oriented investors seeking a 29% discount to intrinsic value.
Market read
Analyst upgrade with a new $1,400 target provides a clear catalyst for short‑term traders and longer‑term investors.
What to watch
Potential regulatory or competitive risks for Vyvgart and upcoming Phase 3 readout could temper upside.
Background
ARGX is a Dutch biotech listed on NASDAQ, known for its antibody therapy Vyvgart targeting rare autoimmune diseases.
Ticker impact
UBS upgraded argenx SE (NASDAQ: ARGX) to Buy and raised its 12‑month price target to $1,400 after late‑stage trial results for Vyvgart.
Potential price appreciation toward the new $1,400 target.
Upgrade is a fresh, material event with a concrete target; traders can act on the new guidance.
Market effects
Biotech sector may see increased interest as a leading rare‑disease therapy shows strong data.
European biotech stocks could benefit from the positive sentiment around a Dutch‑based firm.
Upgrade highlights the value of late‑stage trial successes for global pharma investors.
Counterpoint
The stock may already be priced for the upgrade; valuation remains premium with a high P/E.
Key entities
- AnalystUBS
Upgraded ARGX to Buy and raised price target.
- ProductVyvgart
Flagship drug with positive late‑stage trial results.
